Brief India: Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 and more
In this briefing: Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 Asian Equities: Higher Earnings Estimates, Lower Stock Prices - Nine Notable Sectors Exchanges, Staffing and Internet (Q4FY26E Results Preview): Exchanges hitting new peaks Morning Views Asia - April 15, 2026 Primer: Crisil Ltd (CRISIL IN) - Apr 2026 1. Pharmaceuticals: IPM: 11% growth in Mar-26, 10% in FY26 As per IQVIA, IPM recorded growth for Feb-26 at 11% YoY (vs 12% in Feb-26), unit decline by 0.2% YoY (0.9%% in Feb-26) Growth was led by CVS, anti-diabetes, pain, VMN, and oncology segments, while growth in anti-infective and respiratory was below IPM growth For Q4FY26, IPM grew 12% YoY and FY26 grew 10% YoY, led by ~2.7% volume, 4.4% price, and 2.8% new products. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Asian Equities: Higher Earnings Estimates, Lower Stock Prices - Nine Notable Sectors The resilience of Asian earnings is surprising.